L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:173582 CAPLUS
DOCUMENT NUMBER: 138:221586
TITLE: Preparation of azoles as oral antidiabetic agents.
INVENTOR(S): Bigge, Christopher Franklin; Bridges, Alexander James; Casimiro-Garcia, Augustin; Fakhoury, Stephen Alan; Lee, Helen Tsenwhei; Reed, Jessica Elizabeth; Schaum, Robert Philipp; Schlosser, Kevin Matthew; Sexton, Karen Elaine; Zhou, Hairong
PATENT ASSIGNEE(S): Warner Lambert Co., USA
SOURCE: PCT Int. Appl., 333 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018553	A1	20030306	WO 2002-IB2843	20020715
WO 2003018553	C1	20040408		

W: AE, AM, BA, BG, CA, CO, CU, DE, DK, EE, FI, GB, GE, GH, HR, ID, IL, IN, JP, KE, KZ, LK, LR, LU, MA, MN
RW: GH, GM, MW, SD, SL, TZ, ZM, AT, BE, CH, CY, SK, TR, BF, CG, CI, GA
EP 1423363 A1 20040602 EP 2002-745739 20020715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
US 2003171377 A1 20030911 US 2002-225716 20020822
PRIORITY APPLN. INFO.: US 2001-315728P P 20010829
US 2001-322123P P 20010914
US 2002-369788P P 20020403
WO 2002-IB2843 W 20020715
OTHER SOURCE(S): MARPAT 138:221586
AB AXQYC(B)(D)ZE [A = (substituted) (fused) aryl, heteroaryl, cycloalkyl, heterocycloalkyl; X = CH2O, CH2CH2O, (CH2)3, CH2C.tplbond.C, CH2CH:CH; Q = (substituted) (fused) aryl, heteroaryl; Y, Z = null, (CR1R2)n, (CR3R4)m; R1-R4 = H, halo, alkyl, OH, alkoxy; m, n = 1-3; B = H, halo, alkyl, haloalkyl, alkoxy; D = H, (substituted) arylamino, alkanoyl, PhCO, aryl, heteroaryl, cycloalkyl, heterocycloalkyl; E = COR5; R5 = alkyl, OH, alkoxy, amino, sulfonylamino, substituted heteroaryl, dioxothiazolyl, etc.; with provisos], were prepd. Thus, (S)-tyrosine Me ester, 2,5-dimethoxytetrahydrofuran, and NaOAc were heated in aq. HOAc at

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
100.degree. for 20 min. to give 35% pyrrolotyrosine Me ester. This was stirred with 2-(5-methyl-2-phenyloxazol-4-yl)ethanol, Ph3P, and di-Et azodicarboxylate in THF for 18 h to give 51% Me (S)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-pyrrol-1-ylpropionate. The latter was stirred with LiOH in THF/H2O to give 51% (S)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-pyrrol-1-ylpropionic acid. In a 3T3-L1 adipocyte differentiation assay, title compds. at 5 .mu.M showed 2-183% of the activity of BRL 49653 pos. control. A drug formulation is given.
IT 501029-25-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compd.; prepn. of azoles as oral antidiabetic agents)
RN 501029-25-0 CAPLUS
CN Benzeneacetic acid, .alpha.-[[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:927184 CAPLUS
DOCUMENT NUMBER: 138:14048
TITLE: Preparation of oxazolylethoxyphenylprolines and related compounds as antidiabetic and antiobesity agents.
INVENTOR(S): Cheng, Peter T.; Jeon, Yoon; Wang, Wei
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096357	A2	20021205	WO 2002-US16628	20020523
WO 2002096357	A3	20030925		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003092697 A1 20030515 US 2002-153342 20020522
EP 1401433 A2 20040331 EP 2002-737192 20020523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: US 2001-294505P P 20010530
WO 2002-US16628 W 20020523
OTHER SOURCE(S): MARPAT 138:14048
GI

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, with an alkenyl or alkynyl bond in the chain, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; provided that .gtoreq.1 of x2 and x3 .noteq. 0; X1 = CH, N; X2 = C, N, O, S; X3 = C, N; X4 = C, N, O, S provided that .gtoreq.1 of X2, X3, X4 = N; in each of X1-X4, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3 = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, heteroarylheteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, aryloxyheteroarylalkyl, heteroarylalkyloxyarylalkyl, arylarylalkyl, arylalkenylarylalkyl, arylaminoarylalkyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; Z = (CH2)x4, (CH2)x5, (CH2)x6O(CH2)x7; x4 = 1-5; x5 = 2-5; x6, x7 = 0-4], were prepd. as antidiabetic and antiobesity agents (no data). Thus, title compd. (II) was prepd. in 6 steps.
IT 477719-54-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of oxazolylethoxyphenylprolines and related compds. as antidiabetic and antiobesity agents)
RN 477719-54-3 CAPLUS

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 4-Pentenoic acid, 2-[[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:502825 CAPLUS
DOCUMENT NUMBER: 137:63237
TITLE: Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as antidiabetic and antiobesity agents
INVENTOR(S): Cheng, Peter T.; Devasthale, Pratik; Jeon, Yoon; Chen, Sean; Zhang, Hao
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S., 190 pp., Cont.-in-part of U.S. Ser. No. 664,598.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6414002	B1	20020702	US 2001-812960	20010320
US 2003069275	A1	20030410	US 2002-80965	20020222
US 2003087935	A1	20030508	US 2002-81075	20020222
US 6727271	B2	20040427		
US 2003096846	A1	20030522	US 2002-80981	20020222
US 6653314	B2	20031125		

PRIORITY APPLN. INFO.: US 1999-155400P P 19990922
US 2000-664598 A2 20000918
US 2001-812960 A3 20010320
OTHER SOURCE(S): MARPAT 137:63237
GI



I



II

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB Title compds. I [wherein Q = C, N; A = O, S; B = (CH2)x; Z = O, bond; X = CH, N; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, amino; R3 = H, alkyl, aralkyl, aryloxycarbonyl, alkoxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R2a, R2b, R2c = H, alkyl, alkoxy, halo, amino; Y = CO2R4, 1-tetrazolyl, PO(OR4a)R5; R4 = H, alkyl, prodrug or ester; R4a = H, prodrug ester; R5 = alkyl, aryl; x = 1-4; m, n = 1, 2] were prepd. as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). For example, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph3P, and DEAD were stirred in THF at 0.degree.-room temp. to give 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde (65%). Addn. of N-benzylglycine Et ester and NaBH(OAc)3 in 1,2-dichloroethane afforded the benzylamine deriv. (55%), which was stirred with aq. NaOH in MeOH for 14 h to give the title compd. II (71%). I are useful for the treatment of diabetes, esp. Type II diabetes, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, atherosclerosis, and related diseases (no data).

IT **331739-69-6P**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 331739-69-6 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT **331746-66-8**, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, mono(trifluoroacetate)
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 331746-66-8 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 331739-69-6
CMF C21 H22 N2 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT **331746-22-6P**, Alanine, 2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 331746-22-6 CAPLUS
CN Alanine, 2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:228872 CAPLUS
DOCUMENT NUMBER: 134:266299
TITLE: Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as antidiabetic and antiobesity agents.
INVENTOR(S): Cheng, Peter T. W.; Devasthale, Pratik; Jeon, Yoon T.; Chen, Sean; Zhang, Hao
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 362 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021602	A1	20010329	WO 2000-US25710	20000919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1218361	A1	20020703	EP 2000-965172	20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014189	A	20020820	BR 2000-14189	20000919
TR 200200732	T2	20021021	TR 2002-200200732	20000919
JP 2003509503	T2	20030311	JP 2001-524981	20000919
ZA 2002000937	A	20030502	ZA 2002-937	20020201
NO 2002001408	A	20020514	NO 2002-1408	20020321

PRIORITY APPLN. INFO.: US 1999-155400P P 19990922
WO 2000-US25710 W 20000919
OTHER SOURCE(S): MARPAT 134:266299
GI

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB Title compds. [I; Q = C, N; A = O, S; B = (CH2)x; Z = O, bond; X = CH, N; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, amino; R3 = H, alkyl, aralkyl, aryloxycarbonyl, alkoxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R2a, R2b, R2c = H, alkyl, alkoxy, halo, amino; Y = CO2R4, 1-tetrazolyl, PO(OR4a)R5; R4 = H, alkyl, prodrug or ester; R4a = H, prodrug ester; R5 = alkyl, aryl; x = 1-4; m, n = 1, 2], were prepd. as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). Thus, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph3P, and DEAD were stirred in THF at 0.degree.-room temp. to give 65% 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde. This was stirred 12 h with N-benzylglycine Et ester and NaBH(OAc)3 in 1,2-dichloroethane to give 55% benzylamine deriv., which was stirred 14 h with aq. NaOH in MeOH to give 71% title compd. (II).

IT **331739-69-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)
RN 331739-69-6 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **331746-66-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)
RN 331746-66-8 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 331739-69-6
CMF C21 H22 N2 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT **331746-22-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)
RN 331746-22-6 CAPLUS
CN Alanine, 2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

```
=>  file beil
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    21.37     182.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -2.94      -2.94

FILE 'BEILSTEIN' ENTERED AT 09:09:28 ON 02 JUL 2004
COPYRIGHT (c) 2004 Beilstein-Institut zur Foerderung der Chemischen
Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE RELOADED ON OCTOBER 20, 2002
FILE LAST UPDATED ON JUNE 15, 2004

FILE COVERS 1771 TO 2003.
*** FILE CONTAINS  8,997,153 SUBSTANCES ***

>>> PLEASE NOTE: Reaction data and substance data are stored in
    separate documents and can not be searched together in one
    query.
    Reaction data for BEILSTEIN compounds may be displayed
    immediately with the display codes PRE (preparations) and REA
    (reactions). A substance answer set retrieved after the search
    for a chemical name, a molecular formula or a structure search
    for example can be restricted to compounds with available
    reaction information by concatenation with PRE/FA, REA/FA or
    more general with RX/FA. The BEILSTEIN Registry Number (BRN)
    is the link between a BEILSTEIN compound and belonging reactions.
    For more detailed reaction searches BRNs can be selected from
    substance answer sets and searched in the next step as reaction
    partner BRNs - Reactant (RX.RBRN) or Product BRN (RX.PBRN).
    After a search for reaction details substance documents
    associated with reactants or products may be retrieved by
    searching RX.PBRNs or RX.RBRNs as BRNs. <<<


>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

*********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.               *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE  *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE         *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                       *
* FOR PRICE INFORMATION SEE HELP COST                               *
*********************************************************************

=> s l1
SAMPLE SEARCH INITIATED 09:09:35 FILE 'BEILSTEIN'
SAMPLE SCREEN SEARCH COMPLETED -      0 TO ITERATE
```

```
100.0% PROCESSED       0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO         0
PROJECTED ANSWERS:               0 TO         0

L5            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:09:43 FILE 'BEILSTEIN'
FULL SCREEN SEARCH COMPLETED -      0 TO ITERATE

100.0% PROCESSED       0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.04

L6            0 SEA SSS FUL L1

=> d his

     (FILE 'HOME' ENTERED AT 09:06:23 ON 02 JUL 2004)

     FILE 'REGISTRY' ENTERED AT 09:06:28 ON 02 JUL 2004
L1              STRUCTURE UPLOADED
L2            0 S L1
L3            5 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 09:07:33 ON 02 JUL 2004
L4            4 S L3

     FILE 'BEILSTEIN' ENTERED AT 09:09:28 ON 02 JUL 2004
L5            0 S L1
L6            0 S L1 FULL

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	182.79

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.94

STN INTERNATIONAL LOGOFF AT 09:10:04 ON 02 JUL 2004